ORPHENGESIC FORTE: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Galt Pharms	ORPHENGESIC FORTE	aspirin; caffeine; orphenadrine citrate	TABLET;ORAL	075141	ANDA	Poly Pharmaceuticals, Inc.	50991-999-60	60 TABLET, MULTILAYER in 1 BOTTLE (50991-999-60)	2019-04-01
Galt Pharms	ORPHENGESIC FORTE	aspirin; caffeine; orphenadrine citrate	TABLET;ORAL	075141	ANDA	Galt Pharmaceuticals, LLC	61825-302-60	60 TABLET in 1 BOTTLE, PLASTIC (61825-302-60)	2020-06-08
Galt Pharms	ORPHENGESIC FORTE	aspirin; caffeine; orphenadrine citrate	TABLET;ORAL	075141	ANDA	Galt Pharmaceuticals, LLC	61825-305-60	60 TABLET in 1 BOTTLE, PLASTIC (61825-305-60)	2022-05-16
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the key suppliers for Orphengesic Forte, a fixed-dose combination drug comprising orphenadrine citrate, aspirin, and caffeine. The analysis focuses on the Active Pharmaceutical Ingredient (API) for orphenadrine citrate, as well as common excipients found in oral solid dosage forms. Understanding the supply chain for these components is critical for assessing manufacturing reliability, potential cost fluctuations, and competitive landscape.

ORPHENADRINE CITRATE API SUPPLIERS

Orphenadrine citrate is the primary active pharmaceutical ingredient of Orphengesic Forte. Its synthesis involves multiple steps, and the availability and cost of precursors can influence overall API production. The market for orphenadrine citrate API is characterized by a limited number of manufacturers, primarily located in Asia.

Key Orphenadrine Citrate API Manufacturers

Identifying direct API manufacturers requires access to proprietary supply chain data and patent filings. However, general industry knowledge and typical sourcing patterns for generic APIs suggest the following types of entities are likely involved, either directly or indirectly, in the production or distribution of orphenadrine citrate API.

Specialty Chemical Manufacturers: Companies with expertise in complex organic synthesis are primary candidates. These firms often produce APIs for multiple pharmaceutical clients.
Contract Manufacturing Organizations (CMOs): CMOs specializing in API synthesis and production for generic drug manufacturers are a significant part of the supply chain.

While specific company names for orphenadrine citrate API are not publicly disclosed in a comprehensive registry, due diligence for pharmaceutical companies typically involves direct engagement and audits of potential suppliers. Factors such as Good Manufacturing Practice (GMP) compliance, regulatory history (e.g., FDA inspections, CEP certifications), production capacity, and pricing are paramount in supplier selection.

Global Production Hubs for Orphenadrine Citrate API

The production of many generic APIs, including orphenadrine citrate, is concentrated in specific geographic regions due to cost advantages and established chemical manufacturing infrastructure.

China: A dominant global player in API manufacturing, China offers extensive chemical synthesis capabilities and competitive pricing.
India: Another major hub for API production, India has a strong pharmaceutical manufacturing base and a significant number of GMP-certified facilities.

Manufacturers in these regions often supply to formulators globally, either directly or through distributors. The regulatory scrutiny on APIs from these regions is high, requiring robust quality control and documentation from suppliers.

ASPIRIN AND CAFFEINE API SUPPLIERS

Aspirin (acetylsalicylic acid) and caffeine are widely available commodity APIs. Their production is less specialized than orphenadrine citrate, leading to a broader supplier base and generally more stable pricing.

Aspirin (Acetylsalicylic Acid) Suppliers

Aspirin is produced through the esterification of salicylic acid with acetic anhydride. Major chemical companies and pharmaceutical ingredient manufacturers globally produce aspirin.

Major Chemical Corporations: Companies with large-scale industrial chemical production facilities often manufacture aspirin as a high-volume product.
Dedicated Pharmaceutical Ingredient Manufacturers: Numerous companies specialize in producing APIs like aspirin, serving the pharmaceutical industry.

The global production capacity for aspirin is substantial, ensuring consistent availability. Key producing regions include North America, Europe, and Asia.

Caffeine Suppliers

Caffeine is synthesized or extracted from natural sources. Both synthetic and natural caffeine are widely available.

Chemical Synthesis Companies: Many chemical manufacturers produce synthetic caffeine.
Natural Extraction Companies: Companies that process coffee beans or tea leaves may also produce and supply natural caffeine.

Caffeine is a widely used ingredient in pharmaceuticals, food, and beverages, contributing to a robust and diversified supply chain.

EXCIPIENT SUPPLY CHAIN

Orphengesic Forte, as an oral solid dosage form, will utilize various excipients to facilitate manufacturing, enhance stability, and ensure proper drug release. The selection and sourcing of these excipients are crucial for formulation success and product quality.

Common Excipients in Oral Solid Dosage Forms

Excipients are broadly categorized by their function: binders, fillers, disintegrants, lubricants, and coatings.

Binders

Binders are used to hold the active ingredients and other powdered excipients together in a tablet granulation.

Microcrystalline Cellulose (MCC): A widely used binder and filler. Major global suppliers include companies like DuPont, J.J. Thomson, and various Chinese and Indian manufacturers.
Povidone (Polyvinylpyrrolidone - PVP): Another common binder. BASF and Ashland are significant global suppliers.
Hydroxypropyl Methylcellulose (HPMC): Used as a binder and for controlled-release applications. Dow Chemical and Shin-Etsu Chemical are prominent producers.

Fillers (Diluents)

Fillers add bulk to the formulation, allowing for practical tablet size.

Lactose Monohydrate: A very common filler, particularly in tablets. Companies like Foremost Farms and Hilmar Ingredients are key suppliers.
Starch (Corn Starch, Potato Starch): Widely available and cost-effective fillers. Cargill and Tate & Lyle are major starch producers.
Dicalcium Phosphate (DCP): Used as a filler and binder. Companies like Innophos and several Chinese manufacturers supply DCP.

Disintegrants

Disintegrants promote the breakup of the tablet into smaller fragments, facilitating dissolution.

Croscarmellose Sodium: A superdisintegrant. J. Rettenmaier & Söhne (JRS) and Ashland are leading suppliers.
Sodium Starch Glycolate: Another common disintegrant. Roquette and Avebe are significant producers.
Crosspovidone: Used as a disintegrant and solubilizer. BASF is a key supplier.

Lubricants

Lubricants reduce friction between the tablet and the die wall during compression, preventing sticking.

Magnesium Stearate: The most common lubricant. Companies like Peter Cremer GmbH and Mallinckrodt Pharmaceuticals are producers.
Stearic Acid: Used as a lubricant and emulsifier. Multiple global chemical companies produce stearic acid.

Glidants

Glidants improve the flowability of powder blends.

Colloidal Silicon Dioxide: Widely used as a glidant and adsorbent. Evonik Industries and Cabot Corporation are major suppliers.

Excipient Supplier Landscape

The excipient market is more fragmented than the API market, with numerous global and regional suppliers. For pharmaceutical applications, excipient manufacturers must adhere to strict quality standards, including pharmacopoeial requirements (e.g., USP, EP, JP) and GMP.

Global Conglomerates: Large chemical and ingredient companies often have dedicated divisions for pharmaceutical excipients.
Specialized Excipient Manufacturers: Several companies focus solely on producing high-purity excipients for the pharmaceutical industry.
Regional Suppliers: Local manufacturers cater to specific geographic markets, offering competitive pricing and logistical advantages.

Due diligence for excipient sourcing involves evaluating supplier reliability, quality control systems, regulatory compliance, and supply chain resilience, particularly for critical excipients.

SUPPLY CHAIN RISK ASSESSMENT

The supply chain for Orphengesic Forte presents several areas for risk mitigation and strategic planning.

API Supply Risks

Geographic Concentration: Reliance on a limited number of API manufacturers, predominantly in China and India, exposes the supply chain to geopolitical risks, regulatory changes, natural disasters, and trade disputes.
Quality and Regulatory Compliance: Ensuring consistent quality and GMP compliance from all API suppliers is paramount. Any disruption due to quality issues or regulatory actions can halt production.
Price Volatility: While aspirin and caffeine prices are relatively stable, orphenadrine citrate API pricing can fluctuate based on precursor costs and supplier capacity.

Excipient Supply Risks

Single Sourcing: For critical excipients, reliance on a single supplier, even a large one, poses a risk. Dual sourcing strategies are often employed.
Quality Variability: While excipients are generally less regulated than APIs, maintaining consistent quality is essential for tablet performance. Batch-to-batch variability can impact manufacturing.
Supply Chain Disruptions: Global events, transportation issues, and raw material shortages can affect excipient availability.

Mitigation Strategies

Supplier Qualification and Auditing: Rigorous qualification processes, including on-site audits and extensive documentation review, are necessary for all API and excipient suppliers.
Dual/Multiple Sourcing: Where feasible, securing supply from at least two qualified suppliers for critical raw materials can reduce dependence on a single source.
Inventory Management: Maintaining appropriate inventory levels for APIs and key excipients can buffer against short-term supply disruptions.
Geographic Diversification: Exploring suppliers in different geographic regions can mitigate geopolitical and localized risks.
Contractual Agreements: Robust contracts with suppliers that include clear quality specifications, delivery terms, and contingency plans are vital.

KEY TAKEAWAYS

Orphengesic Forte relies on orphenadrine citrate API, with limited global manufacturers primarily located in China and India.
Aspirin and caffeine APIs are commodity products with a broad and stable supply base.
Excipient supply is more diversified, with global and regional players providing binders, fillers, disintegrants, and lubricants.
Key risks include geographic concentration of API manufacturing, quality control, and potential disruptions in the global supply chain for both APIs and excipients.
Robust supplier qualification, dual sourcing for critical components, and strategic inventory management are essential for ensuring manufacturing continuity.

FREQUENTLY ASKED QUESTIONS

What are the primary regulatory requirements for API suppliers of orphenadrine citrate?

API suppliers must adhere to Good Manufacturing Practices (GMP) as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national health authorities. This includes detailed documentation, quality control, and facility inspections.

How does the pricing of orphenadrine citrate API compare to aspirin and caffeine?

Orphenadrine citrate API is generally more expensive per unit mass than aspirin and caffeine, which are high-volume commodity chemicals. The complexity of orphenadrine citrate synthesis contributes to its higher cost.

What is the typical lead time for sourcing specialized pharmaceutical excipients?

Lead times for specialized pharmaceutical excipients can range from 4 to 12 weeks, depending on the supplier, order volume, and current market demand. This can be longer for custom-specified or novel excipients.

Are there specific patent considerations for orphenadrine citrate API synthesis that could impact supply?

While the patent for Orphengesic Forte itself may have expired or be expiring, process patents for the synthesis of orphenadrine citrate API might still be in effect or recently expired. Manufacturers often develop proprietary synthesis routes to achieve cost efficiencies or higher purity, which can influence their competitive standing and market access.

What measures can be taken to ensure the quality consistency of excipients from different suppliers?

Ensuring quality consistency involves establishing detailed material specifications that align with pharmacopoeial standards (e.g., USP, EP), conducting rigorous incoming material testing, qualifying suppliers through audits, and implementing a robust change control process with suppliers for any modifications to their manufacturing processes.

CITATIONS

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) for Drugs. Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-drugs [2] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from https://www.ema.europa.eu/en/human-regulatory/manufacturing/good-manufacturing-practice

Suppliers and packagers for ORPHENGESIC FORTE